JP2020517631A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020517631A5 JP2020517631A5 JP2019556830A JP2019556830A JP2020517631A5 JP 2020517631 A5 JP2020517631 A5 JP 2020517631A5 JP 2019556830 A JP2019556830 A JP 2019556830A JP 2019556830 A JP2019556830 A JP 2019556830A JP 2020517631 A5 JP2020517631 A5 JP 2020517631A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- oligonucleotide
- population
- item
- oligonucleotides
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims description 60
- 108091034117 Oligonucleotide Proteins 0.000 claims description 50
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 22
- 150000003904 phospholipids Chemical class 0.000 claims description 17
- 230000007935 neutral effect Effects 0.000 claims description 8
- 229910019142 PO4 Inorganic materials 0.000 claims description 7
- 239000002502 liposome Substances 0.000 claims description 7
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 7
- 239000010452 phosphate Substances 0.000 claims description 7
- 150000004713 phosphodiesters Chemical class 0.000 claims description 7
- 239000002773 nucleotide Substances 0.000 claims description 6
- 125000003729 nucleotide group Chemical group 0.000 claims description 6
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 3
- 239000006185 dispersion Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000002777 nucleoside Substances 0.000 claims description 2
- 150000003833 nucleoside derivatives Chemical class 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 108091033319 polynucleotide Proteins 0.000 claims description 2
- 239000002157 polynucleotide Substances 0.000 claims description 2
- 102000040430 polynucleotide Human genes 0.000 claims description 2
- 239000004094 surface-active agent Substances 0.000 claims 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762487420P | 2017-04-19 | 2017-04-19 | |
| US62/487,420 | 2017-04-19 | ||
| PCT/US2018/028263 WO2018195250A1 (en) | 2017-04-19 | 2018-04-19 | P-ethoxy nucleic acids for igf-1r inhibition |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020517631A JP2020517631A (ja) | 2020-06-18 |
| JP2020517631A5 true JP2020517631A5 (enExample) | 2021-05-20 |
| JP7186721B2 JP7186721B2 (ja) | 2022-12-09 |
Family
ID=63856102
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019556830A Active JP7186721B2 (ja) | 2017-04-19 | 2018-04-19 | Igf-1r阻害のためのp-エトキシ核酸 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20210115451A1 (enExample) |
| EP (1) | EP3612162A4 (enExample) |
| JP (1) | JP7186721B2 (enExample) |
| KR (1) | KR102657218B1 (enExample) |
| CN (1) | CN110650727A (enExample) |
| AU (1) | AU2018255353B2 (enExample) |
| CA (1) | CA3057974A1 (enExample) |
| WO (1) | WO2018195250A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102755601B1 (ko) | 2015-10-14 | 2025-01-17 | 바이오-패쓰 홀딩스 인크. | 리포좀 제제를 위한 p-에톡시 핵산 |
| US10927379B2 (en) | 2016-09-16 | 2021-02-23 | Bio-Path Holdings, Inc. | Combination therapy with liposomal antisense oligonucleotides |
| IL269608B2 (en) | 2017-04-19 | 2024-06-01 | Bio Path Holdings Inc | Compositions comprising p-ethoxy nucleic acids for stat3 inhibition for use in treating cancer or autoimmune disease |
| US12234457B2 (en) | 2017-04-19 | 2025-02-25 | Bio-Path Holdings, Inc. | P-ethoxy nucleic acids for BCL2 inhibition |
| CN114369130B (zh) * | 2021-12-28 | 2023-10-03 | 杭州天龙药业有限公司 | 修饰的硫代寡核苷酸及其应用 |
| KR20250164828A (ko) | 2023-03-30 | 2025-11-25 | 레볼루션 메디슨즈, 인크. | Ras gtp 가수분해 유도를 위한 조성물 및 이의 용도 |
| TW202508595A (zh) | 2023-05-04 | 2025-03-01 | 美商銳新醫藥公司 | 用於ras相關疾病或病症之組合療法 |
| WO2025034702A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Rmc-6291 for use in the treatment of ras protein-related disease or disorder |
| WO2025080946A2 (en) | 2023-10-12 | 2025-04-17 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6015886A (en) * | 1993-05-24 | 2000-01-18 | Chemgenes Corporation | Oligonucleotide phosphate esters |
| US5855911A (en) * | 1995-08-29 | 1999-01-05 | Board Of Regents, The University Of Texas System | Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides |
| US6977244B2 (en) * | 1996-10-04 | 2005-12-20 | Board Of Regents, The University Of Texas Systems | Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides |
| US7704962B1 (en) * | 1997-10-03 | 2010-04-27 | Board Of Regents, The University Of Texas System | Small oligonucleotides with anti-tumor activity |
| AU5479899A (en) * | 1998-08-13 | 2000-03-06 | Thomas Jefferson University | Treatment of tumors with oligonucleotides directed to insulin-like growth factor-i receptor |
| US20030180789A1 (en) * | 1998-12-30 | 2003-09-25 | Dale Roderic M.K. | Arrays with modified oligonucleotide and polynucleotide compositions |
| AU2003207708A1 (en) * | 2002-02-20 | 2003-09-09 | Sirna Therapeutics, Inc. | Rna interference mediated inhibition of map kinase genes |
| US9150605B2 (en) * | 2002-11-05 | 2015-10-06 | Isis Pharmaceuticals, Inc. | Compositions comprising alternating 2′-modified nucleosides for use in gene modulation |
| US10206942B2 (en) * | 2015-04-10 | 2019-02-19 | Thomas Jefferson University | Methods and compositions for treating cancers and enhancing therapeutic immunity by selectively reducing immunomodulatory M2 monocytes |
| KR102755601B1 (ko) * | 2015-10-14 | 2025-01-17 | 바이오-패쓰 홀딩스 인크. | 리포좀 제제를 위한 p-에톡시 핵산 |
-
2018
- 2018-04-19 CN CN201880033242.7A patent/CN110650727A/zh active Pending
- 2018-04-19 CA CA3057974A patent/CA3057974A1/en active Pending
- 2018-04-19 KR KR1020197033981A patent/KR102657218B1/ko active Active
- 2018-04-19 US US16/606,433 patent/US20210115451A1/en active Pending
- 2018-04-19 JP JP2019556830A patent/JP7186721B2/ja active Active
- 2018-04-19 EP EP18788505.8A patent/EP3612162A4/en active Pending
- 2018-04-19 WO PCT/US2018/028263 patent/WO2018195250A1/en not_active Ceased
- 2018-04-19 AU AU2018255353A patent/AU2018255353B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020517631A5 (enExample) | ||
| Scheicher et al. | Protamine–oligonucleotide-nanoparticles: Recent advances in drug delivery and drug targeting | |
| JP6768664B2 (ja) | 分子の細胞内送達のためのペプチドおよびナノ粒子 | |
| US20210214728A1 (en) | Compositions for delivery of cargo to cells | |
| US8440811B2 (en) | DNA nanostructures that promote cell-cell interaction and use thereof | |
| JP2021500064A5 (enExample) | ||
| AU2017203714A1 (en) | Immunostimulatory oligonucleotides | |
| IL273980B2 (en) | Phosphorylated tau peptide preparations and uses thereof | |
| AU2012303619B2 (en) | Pathogen and substance traps | |
| JP2020517645A5 (enExample) | ||
| US20170175122A1 (en) | Rna-based compositions and adjuvants for prophylactic and therapeutic treatment | |
| EP2687204B1 (en) | Vector for pulmonary delivery, inducing agent, and uses | |
| JP2015521626A5 (enExample) | ||
| CN101874112A (zh) | 特别是作为免疫刺激剂/佐剂的式(Ⅰ):G1XmGn或式(Ⅱ):C1XmCn的核酸 | |
| WO2011049750A1 (en) | Multifunctional aptamer-nucleic acid nanostructures for tumor-targeted killing | |
| TW201723178A (zh) | 具拮抗pdl1功能的適體分子於癌症治療之應用 | |
| JPH11504926A (ja) | 核酸リガンド複合体 | |
| JP2021500016A5 (enExample) | ||
| JP2020526530A5 (enExample) | ||
| JP2019534899A (ja) | 脂質ナノ粒子用膜材料組成物 | |
| KR20250002732A (ko) | 중추 신경계 전달용 지질 나노입자 제제 | |
| JP2020517646A5 (enExample) | ||
| CN109464397A (zh) | 一种基于生物矿化的氧化石墨烯多药共载系统及其制备方法和应用 | |
| JP6715775B2 (ja) | 非凝集性免疫賦活化オリゴヌクレオチド | |
| JPWO2020002540A5 (enExample) |